Roncarolo
Daniela Roncarolo, Milano IT
Patent application number | Description | Published |
---|---|---|
20090304752 | HYPOALLERGENIC VARIANTS OF THE MAJOR ALLERGEN FROM BETULA VERRUCOSA POLLEN - The invention provides hypoallergenic variants of Bet v 1 major allergen from | 12-10-2009 |
20100297188 | ALLERGENS AND ALLERGOIDS FROM BEE VENOM - The present invention concerns the preparation of purified allergens and allergoids, both derived from whole bee venom, for the desensitisation (immunotherapy) of subjects affected by a specific allergy. In particular, the present invention concerns a preparation for immunotherapy based on purified bee venom, characterised in that said bee venom is essentially mellitin-free. In addition, the preparation of a monomeric allergoid obtainable through the carbamylation or thiocarbamylation reaction of said mellitin-free bee venom, is described. Said allergoid, being characterised by reduced IgE-binding activity, may be a safer and more effective candidate for specific immunotherapy. | 11-25-2010 |
20100310590 | HYPOALLERGENIC VARIANTS OF THE MAJOR ALLERGEN FROM BETULA VERRUCOSA POLLEN - The invention provides hypoallergenic variants of Bet v 2 major allergen from | 12-09-2010 |
20120114699 | Allergoids Derived from Allergens - Modified allergens having reduced allergenicity compared to corresponding native allergenic material, wherein all or a part of the primary amine groups of the lysine and arginine residues of the allergenic molecules are functionalized and the modified allergens have the structure | 05-10-2012 |
20140294878 | HYPOALLERGENIC VARIANTS OF MAL D 1, THE MAJOR ALLERGEN FROM MALUS DOMESTICA - Disclosed are hypoallergenic variants of Mal d 1, the major allergen from | 10-02-2014 |
20140328881 | HYPOALLERGENIC VARIANTS OF PHL P 5, THE MAJOR ALLERGEN FROM PHLEUM PRATENSE - Disclosed are hypoallergenic variants of PhI p 5, the major allergen from | 11-06-2014 |
20150259378 | ALLERGOIDS DERIVED FROM ALLERGENES - A method of making and a modified allergen having reduced allergenicity and preserved immunogenicity compared to corresponding native allergenic material. The preserved immunogenicity is elicited by a IgG-mediated antibody response, all or part of the primary amine groups of the lysine residues of the native allergenic material are functionalized with carbamoyl or thiocarbamoyl moieties, and all or part of the primary amine groups of the arginine residues of the carbamoyl- or thiocarbamoyl functionalized allergenic material are further functionalized with dialdehyde or diketal moieties. The raw allergenic material is selected from the group consisting of DP mites extract, Der p1, ovalbumin and Lipid Transfer Protein (LTP), the average percentage of modified primary amine groups of the lysine ranges between 75% and 100%; and the average percentage of the substituted arginine residues ranges between 25% and 10%. | 09-17-2015 |
Davide Roncarolo, Pianezza IT
Patent application number | Description | Published |
---|---|---|
20160023719 | LATCHING DEVICE FOR A MOVABLE PLATFORM - A movable platform structure including a base structure, a platform and an articulated system which connects the platform to the base structure, wherein the platform is movable between a raised position which is horizontally adjacent to the base structure and a lowered position which is horizontally far from the base structure. The platform assembly further includes a latching device switchable into a stable locking position for locking the platform against the base structure when the platform is in the raised position. | 01-28-2016 |
Maria Grazia Roncarolo, Milano IT
Patent application number | Description | Published |
---|---|---|
20090010950 | EX-VIVO ISOLATED CD25+CD4+ T CELLS WITH IMMUNOSUPPRESSIVE ACTIVITY AND USES THEREOF - Ex-vivo isolated human CD25 | 01-08-2009 |
20100041145 | TOLEROGENIC DENDRITIC CELLS, METHOD FOR THEIR PRODUCTION AND USES THEROF - The present invention relates to a tolerogenic dendritic cell population (Tr-DC) capable of generating a population of T cells having regulatory activity, method of production and uses thereof. Furthermore, soluble HLA-G promotes the differentiation of a population of T cells with regulatory activity. | 02-18-2010 |
Maria Grazia Roncarolo, Segrate Mi IT
Patent application number | Description | Published |
---|---|---|
20080279829 | Phenyl-(4-Phenyl-Pyrimidin-2-Yl)-Amines For Enhancing Immunotolerance - The use of a phenyl-(4-phenyl-pyrimidin-2-yl)-amine for the preparation of a medicament for enhancing immunotolerance in a mammal; and uses, methods, processes and pharmaceutical combinations and compositions comprising such phenyl-(4-phenyl-pyrimidin-2-yl)-amine. | 11-13-2008 |
20150132272 | COMPOSITIONS AND METHODS FOR DIMINISHING AN IMMUNE RESPONSE - The invention is based upon the discovery that T regulatory type 1 (Tr1) cells express particular cell surface markers that allow for their selection, enrichment, isolation, purification and administration. The ability to use the particular markers described herein to select, enrich, isolate, purity and administer Tr1 cells allows for improved methods of Tr1 therapies for treating a wide variety of diseases and disorders. | 05-14-2015 |
Maria Grazia Roncarolo, Milan IT
Patent application number | Description | Published |
---|---|---|
20110218234 | GENE VECTOR FOR INDUCING TRANSGENE-SPECIFIC IMMUNE TOLERANCE - A gene vector adapted for transient expression of a transgene in a peripheral organ cell comprising a regulatory sequence operably linked to a transgene wherein the regulatory sequence prevents or reduces expression of said transgene in hematopoietic lineage cells. | 09-08-2011 |
Maria Grazia Roncarolo, Segrate (milan) IT
Patent application number | Description | Published |
---|---|---|
20080279826 | Method for Expanding Cd4+ Cd25+ T Regulator Cells - A method for generating/expanding in vitro a CD4 | 11-13-2008 |
Maria Grazia Roncarolo, Basel CH
Patent application number | Description | Published |
---|---|---|
20100183602 | Induction of Tolerogenic Phenotype in Mature Dendritic Cells - The present invention relates to the use of a CD45 binding molecule to modulate the function of Dendritic cells. In particular the present invention relates to the use of a CD45 binding molecule to induce tolerogenic dendritic cells, useful in the treatment of diseases or disorders such as autoimmune diseases, transplant rejection. | 07-22-2010 |